NCI Solicits Views on Cancer Study Invention Rights
Published Date: 6/27/2025
Notice
Summary
The National Cancer Institute’s Division of Cancer Prevention wants your thoughts on a new rule about who owns inventions made during certain cancer studies. This rule would affect groups working with NCI-funded projects that use special tech or drugs from NCI collaborators. If approved, it could change how intellectual property is shared in current and future studies, so get ready to weigh in soon!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
New NCI 'IP Option' for Collaborators
If you run or work for an entity that conducts Division of Cancer Prevention (DCP)‑funded clinical studies and your project uses a proprietary agent or technology provided by an NCI collaborator, a proposed standard policy called the “IP Option” could apply to you. The policy would be added as a term to applicable existing and future DCP funding agreements and could change how intellectual property developed by funding recipients is handled. The National Cancer Institute is asking for public comments on this proposed policy.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in